Looks like both the CTAD and ASN Kidney Week posters are up on the RVX web site. I haven't had a chance to look at them yet.
Also, Biogen/Eisai presented more on their BAN2401 trial at CTAD. They attempted to salvage their reputation after getting slammed on their trial design and analysis. If you read the headlines, they failed miserably in their attempt. So great opportunity for Resverlogix to impress with the BETonMACE sub study.
BearDownAZ